SMMT - サミット・セラピュ―ティクス (Summit Therapeutics plc) サミット・セラピュ―ティクス

 SMMTのチャート


 SMMTの企業情報

symbol SMMT
会社名 Summit Therapeutics PLC (サミット・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種    医療関連(Health Care)
概要 事業概要 --   サミット・セラピュ―ティクスはイギリスのバイオ医薬品メ―カ―。既存疾病または治療法のない疾病の新規治療薬の開発、商品化に焦点を当てる。主に、致命的な筋肉消耗疾患のデュシェンヌ型筋ジストロフィ―とクロストリジウム・ディフィシル細菌感染症の治療法の発見、および新規医薬品の開発に注力する。本社所在地はアビングドン。   Summit Therapeutics, empowered by its Discuva Platform, the Company's innovative antibiotic discovery engine, led by Dr. Ventzislav Stefanov and supported by BARDA and Carb-X funding, intends to be the leader in patient and physician friendly paradigm shifting antibiotic innovation. Its new mechanism antibiotics are designed to become the patient-friendly, new era standard-of-care, by working in harmony with the human microbiome to treat prospective patients suffering from infectious disease, initially focussing on Clostridioides difficile infections ("CDI") which is estimated to impact over 3 million patients worldwide annually. Commercialization of ridinilazole for the treatment of CDI is subject to regulatory approvals. The overriding objective of Summit Therapeutics is to create value for patients, hospital infectious disease care givers, community based infectious disease healthcare providers, as well as healthcare payors around the world. Currently, Summit's lead product candidate ridinilazole is engaged in two global phase III trials, Ri-CoDIFy 1 & 2, each enrolling 680 patients vs standard of care (Vancomycin) for the treatment of C. difficile infections.
本社所在地 136a Eastern Avenue Milton Park Abingdon Oxfordshire OX14 4SB GBR
代表者氏名
代表者役職名
電話番号
設立年月日
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 76人
url www.summitplc.com
nasdaq_url https://www.nasdaq.com/symbol/smmt
adr_tso 6262462
EBITDA EBITDA ー
終値(lastsale) 2.03
時価総額(marketcap) 12712797.86
時価総額 時価総額 ―
売上高 売上高 --
企業価値(EV) 企業価値(EV) ー
当期純利益 当期純利益 --
決算概要 決算概要 --

 SMMTのテクニカル分析


 SMMTのニュース

   Summit Therapeutics to Present Breakthrough Research Updates at the 31st Annual ECCMID Conference, including a Top-Rated ePoster  2021/07/01 12:00:00 Intrado Digital Media
Cambridge, MA, July 01, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (the Company) today announced that members of our scientific team will present breakthrough research updates at the 31 st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), which will be held virtually July 9 12. Our three posters to be presented are as follows, one of which was designated as a Top Rated ePoster by the ECCMID conference:
   Summit Therapeutics: A Full Investment Analysis Of This Antibiotic Innovator  2021/06/22 17:25:45 Seeking Alpha
   Summit Therapeutics to join Russell 3000 Index  2021/06/08 11:35:24 Seeking Alpha
   Summit Therapeutics set to join Russell 3000 Index  2021/06/08 11:00:00 Wallstreet:Online
Cambridge, MA, June 08, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) is set to join the broad-market Russell 3000 Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US markets open on June 28, according to a preliminary list of additions posted by FTSE Russell. Annual Russell indexes reconstitution captures the 4,000 largest US stocks
   Summit Therapeutics set to join Russell 3000® Index  2021/06/08 00:00:00 BioSpace
Summit Therapeutics Inc. is set to join the broad-market Russell 3000® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US markets open on June 28, according to a preliminary list of additions posted by FTSE Russell.
   SUMMIT THERAPEU/S (NASDAQ:SMMT) Stock Crosses Above 50-Day Moving Average of $3.41  2020/10/20 01:00:49 Daily Political
SUMMIT THERAPEU/S (NASDAQ:SMMT) shares passed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $3.41 and traded as high as $3.61. SUMMIT THERAPEU/S shares last traded at $3.47, with a volume of 60,582 shares. Separately, Zacks Investment Research cut SUMMIT THERAPEU/S from a “hold” […]
   Summit Therapeutics files for $200M mixed shelf (NASDAQ:SMMT)  2020/10/06 09:46:48 Seeking Alpha
Summit Therapeutics (NASDAQ:SMMT) has filed a prospectus for a $200M mixed shelf offering.
   Summit Therapeutics PLC (SMMT) Outpaces Stock Market Gains: What You Should Know  2020/05/27 21:45:15 Zacks Investment Research
Summit Therapeutics PLC (SMMT) closed at $4.20 in the latest trading session, marking a +1.94% move from the prior day.
   Summit Therapeutics PLC (SMMT) Stock Moves -0.43%: What You Should Know  2020/05/19 21:45:13 Zacks Investment Research
In the latest trading session, Summit Therapeutics PLC (SMMT) closed at $3.48, marking a -0.43% move from the previous day.
   Is Summit Therapeutics (SMMT) Outperforming Other Medical Stocks This Year?  2020/05/13 15:30:09 Zacks Investment Research
Is (SMMT) Outperforming Other Medical Stocks This Year?
   SUMMIT THERAPEU/S (NASDAQ:SMMT) Stock Crosses Above 50-Day Moving Average of $3.41  2020/10/20 01:00:49 Daily Political
SUMMIT THERAPEU/S (NASDAQ:SMMT) shares passed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $3.41 and traded as high as $3.61. SUMMIT THERAPEU/S shares last traded at $3.47, with a volume of 60,582 shares. Separately, Zacks Investment Research cut SUMMIT THERAPEU/S from a “hold” […]
   Summit Therapeutics files for $200M mixed shelf (NASDAQ:SMMT)  2020/10/06 09:46:48 Seeking Alpha
Summit Therapeutics (NASDAQ:SMMT) has filed a prospectus for a $200M mixed shelf offering.
   Summit Therapeutics PLC (SMMT) Outpaces Stock Market Gains: What You Should Know  2020/05/27 21:45:15 Zacks Investment Research
Summit Therapeutics PLC (SMMT) closed at $4.20 in the latest trading session, marking a +1.94% move from the prior day.
   Summit Therapeutics PLC (SMMT) Stock Moves -0.43%: What You Should Know  2020/05/19 21:45:13 Zacks Investment Research
In the latest trading session, Summit Therapeutics PLC (SMMT) closed at $3.48, marking a -0.43% move from the previous day.
   Is Summit Therapeutics (SMMT) Outperforming Other Medical Stocks This Year?  2020/05/13 15:30:09 Zacks Investment Research
Is (SMMT) Outperforming Other Medical Stocks This Year?

 関連キーワード  (― 米国株 サミット・セラピュ―ティクス SMMT Summit Therapeutics plc)

 twitter  (公式ツイッターやCEOツイッターなど)